Back to School: How biopharma can reboot drug development. Access exclusive analysis here
IMCLE was up $4.75 (24%) to $24.60 on 5.1 million shares on Tuesday. The
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury